ID   MZ2-MEL.3.1
AC   CVCL_C5U7
SY   MZ2-Mel 3.1
DR   Wikidata; Q116049845
RX   PubMed=2529220;
RX   PubMed=8566071;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C5U4 ! MZ2-MEL.3.0
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 4
//
RX   PubMed=2529220; DOI=10.1002/ijc.2910440413;
RA   van den Eynde B.J., Hainaut P., Herin M., Knuth A., Lemoine C.,
RA   Weynants P., van der Bruggen P., Fauchet R., Boon T.;
RT   "Presence on a human melanoma of multiple antigens recognized by
RT   autologous CTL.";
RL   Int. J. Cancer 44:634-640(1989).
//
RX   PubMed=8566071; DOI=10.1002/eji.1830260135;
RA   Brichard V.G., Herman J., Van Pel A., Wildmann C., Gaugler B.,
RA   Wolfel T., Boon T., Lethe B.;
RT   "A tyrosinase nonapeptide presented by HLA-B44 is recognized on a
RT   human melanoma by autologous cytolytic T lymphocytes.";
RL   Eur. J. Immunol. 26:224-230(1996).
//